In light of waning immunity to pertussis following receipt of tetanus toxoid, vaccine alone. 4, [8] [9] [10] However, these studies were small (between 82 and 769 subjects) and unable to evaluate rare adverse events.
| INTRODUCTION
The Advisory Committee on Immunization Practices recommends 1 dose of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine for adolescents aged 11 to 18 years and for all adults aged ≥19 years not previously vaccinated. 1, 2 The Advisory Committee on Immunization Practices does not recommend repeated vaccination with Tdap except in pregnant women, who are recommended to receive Tdap during every pregnancy. 3 However, repeated
Tdap vaccination may be necessary to maintain protection against pertussis, possibly with intervals of <10 years. Antibody concentrations to pertussis antigens wane to pre-Tdap levels within 10 years after Tdap vaccination, 4 and vaccine effectiveness may wane within 5 years of Tdap receipt. [5] [6] [7] Limited data are available regarding the safety of repeated Tdap vaccination. In adults and adolescents who had received Tdap as part of Tdap licensure trials, 4 studies did not find an elevated risk of local or systemic reactions to a second dose of Tdap, compared either with Tdap-naïve subjects or with subjects receiving a dose of tetanus toxoid and reduced diphtheria toxoid (Td) vaccine alone. 4, [8] [9] [10] However, these studies were small (between 82 and 769 subjects) and unable to evaluate rare adverse events.
A study of pregnant women found that women who received 
| Exposures of interest
We identified vaccine type and date of receipt of tetanus-containing vaccines by using immunization databases at each MCO. These databases include all vaccinations given to enrollees at each MCO.
The immunization databases at Kaiser Permanente Washington, Marshfield Clinic, and Kaiser Permanente Northwest also exchange data with state immunization information systems, allowing us to identify initial Tdap vaccines received prior to MCO enrollment or outside the MCO health-care system.
| Potential adverse events following vaccination
Consistent with a prior VSD study of Tdap safety, 13 we considered 7 serious potential adverse events: seizure; cranial nerve disorders; limb swelling; pain in limb; cellulitis; paralytic syndromes; and encephalopathy, encephalitis, or meningitis. We did not include Guillain-Barré syndrome as an outcome, 13,14 as preliminary analyses suggested that we would detect fewer than 5 Guillain-Barré syndrome cases in our population. We identified potential adverse events by using International Classification of Diseases, version 9, Clinical Modification (ICD-9-CM) codes assigned to inpatient, outpatient, and emergency department encounters (Table 1) . For each subject, we identified first diagnosis date of each outcome occurring within the observation period after their second tetanus toxoid-containing vaccination. To exclude events which may have had onset prior to vaccination, we excluded any codes during the postvaccination observation period if those specific codes also occurred during the 30 days prior to vaccination.
| Covariates of interest
We used enrollment and medical utilization databases at each MCO to define demographics, MCO enrollment history, indicators of healthcare utilization (numbers of outpatient visits, well care visits, and hospitalizations in the past year), and receipt of other recommended vaccinations. We defined these covariates as of the dates of initial
Tdap and of second tetanus-containing vaccine.
| Analysis
We compared covariate distributions between participants whose second dose of tetanus-containing vaccine was Tdap vs Td. We estimated rates of potential adverse events, with 95% CIs, assuming a Poisson distribution. To compare adverse event rates following Tdap vs Td as the second dose of tetanus-containing vaccine, we estimated rate ratios for each outcome of interest by using Poisson regression. A priori, models were adjusted for age at first receipt of Tdap, number of years between first Tdap and subsequent dose of tetanus-containing vaccine, and year of second dose of tetanus-containing vaccine.
We further included any covariates that altered the rate ratios from this base model by 10% or more. As secondary analyses, we stratified by time between vaccine doses (<3 years vs ≥3 years after Tdap, the median interval between doses). Due to the smaller number of outcomes, these analyses were only adjusted for age at first Tdap, years between doses, and year of second dose. All analyses were conducted by using SAS version 9.4 (SAS Institute, Cary NC).
| RESULTS
We identified 68 915 eligible VSD enrollees who received a dose of Tdap followed by a subsequent dose of tetanus-containing vaccine. 
| Primary analyses

| Stratified by time since first Tdap
Among subjects receiving a second dose of tetanus-containing vaccine <3 years after initial Tdap, receipt of Tdap vs Td was not significantly associated with any study outcome (Figure 1) . Among subjects receiving a second dose ≥3 years after initial Tdap, limb swelling and pain in limb were significantly less common among recipients of
Tdap vs Td ( Figure 1 ); significant associations were not observed for cellulitis, seizure, or cranial nerve disorders. 
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FIGURE 1
Adjusted * rate ratios of adverse events following toxoid and acellular pertussis (Tdap) vs Td as a second dose of tetanuscontaining vaccine following an initial dose of Tdap, overall and stratified by years between vaccine doses * Overall risk ratios adjusted for age at first Tdap, years between first Tdap and second tetanuscontaining vaccine, sex, study site, receipt of human papillomavirus vaccine, and hospitalizations in the prior year. Stratified risk ratios adjusted for age at first Tdap and years between first Tdap and second tetanus-containing vaccine.
reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose. 
